We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial
FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial
October 12, 2012
The FDA reclassified its clinical hold on Repros Therapeutics’ Proellex and will now allow the company to conduct a Phase II trial of low-dose Proellex as a treatment for endometriosis.